Report: Real-world Blincyto spending likely to fall far short of Amgen’s $178K list price

Tracy Staton

When Amgen rolled out its  treatment for an ultra-rare form of leukemia, the California biotech set what seemed to be an eye-watering –$ 178,000 for a typical patient. But some number-crunching of clinical trial data, coupled with documents from the Centers for Medicare and Medicaid Services, suggests that the real-world cost will be much lower.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS